Status:
COMPLETED
Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers
Lead Sponsor:
AstraZeneca
Conditions:
Renal Impairment
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to examine how AZD6140 affects patients with severe kidney disease compared to volunteers with normal kidneys. Subjects in the study will receive one dose of AZD6140.
Eligibility Criteria
Inclusion
- Patients must have severe kidney disease
- Subjects who are matched to the kidney disease patients in terms of weight, age, and sex must have normal kidneys
- All women must be post-menopausal (no longer menstruating) or surgically sterile
Exclusion
- Patients requiring dialysis
- History of allergy to aspirin or clopidogrel
- Have increased bleeding risk (for instance uncontrolled high blood pressure or a recent major injury)
- Recent history of fainting or light-headedness
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2008
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00733265
Start Date
February 1 2007
End Date
September 1 2008
Last Update
December 3 2010
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Phoenix, Arizona, United States
2
Research Site
Anaheim, California, United States
3
Research Site
Miami, Florida, United States
4
Research Site
San Antonio, Texas, United States